Видео ютуба по тегу Gilead Science

Gilead Sciences to acquire Immunomedics in $21 billion deal
Gilead Sciences to acquire Immunomedics in $21 billion deal
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences, Inc: A Commitment To Innovation
Gilead to Buy Kite for $11.9 Billion in Cancer Megadeal
Gilead to Buy Kite for $11.9 Billion in Cancer Megadeal
Inside the Innovation: Pharmaceutical Development and Manufacturing Leaders Share Experiences
Inside the Innovation: Pharmaceutical Development and Manufacturing Leaders Share Experiences
How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines
How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines
Gilead Sciences, CGL and the NHS - Gilead partnering with Drug Treatment Services (and the NHS)
Gilead Sciences, CGL and the NHS - Gilead partnering with Drug Treatment Services (and the NHS)
Gilead Sciences: Creating a pathway to hope
Gilead Sciences: Creating a pathway to hope
Gilead Sciences Presents: Age Positively: Living and Aging Healthy with HIV*
Gilead Sciences Presents: Age Positively: Living and Aging Healthy with HIV*
Gilead COMPASS Initiative
Gilead COMPASS Initiative
Foster City | Local Business Spotlight: Gilead
Foster City | Local Business Spotlight: Gilead
Can Gilead Sciences Maintain Its Dominance in HIV Treatment?
Can Gilead Sciences Maintain Its Dominance in HIV Treatment?
Gilead Sciences CEO Daniel O'Day on the collaboration with biotech firm Galapagos
Gilead Sciences CEO Daniel O'Day on the collaboration with biotech firm Galapagos
Our HIV Anthem: Helping End the HIV Epidemic
Our HIV Anthem: Helping End the HIV Epidemic
Founder Stories: John Martin, Former CEO of Gilead Sciences
Founder Stories: John Martin, Former CEO of Gilead Sciences
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
Gilead Sciences - Hot or Not
Gilead Sciences - Hot or Not
How Gilead Sciences Plans to Beat Merck in Hepatitis C
How Gilead Sciences Plans to Beat Merck in Hepatitis C
Gilead’s Research Scholars Program Supports New Investigations into Rare Liver Disease
Gilead’s Research Scholars Program Supports New Investigations into Rare Liver Disease
Living with PBC for More Than 20 Years – Ellen's Story
Living with PBC for More Than 20 Years – Ellen's Story